Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) said the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, introducing …
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said Hervé Hoppenot recently resigned from its board of directors, effective immediately, formally ending a transition period that followed his long tenure as the …
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported strong early-stage clinical results for an experimental precision antibody that sharply reduced disease markers in patients with essential thrombocythemia, bolstering hopes for a …
Incyte’s Precision Antibody Delivers Striking Results in Rare Blood Cancer Read More WILMINGTON, DE — Incyte Corporation (INCY) is using a sizable equity-based compensation package to secure its new top legal executive, underscoring the company’s emphasis on long-term performance and shareholder alignment …
Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance Read More WILMINGTON, DE — Incyte Corp. (Nasdaq: INCY) appointed Richard Hoffman as executive vice president and general counsel, effective December 1, adding a seasoned life sciences attorney to its top ranks …
Incyte Names Veteran Biopharma Attorney as New General Counsel Read More WILMINGTON, DE — Incyte Corp. (NASDAQ: INCY) will outline upcoming pipeline updates and strategic priorities at two major healthcare investor conferences in early December. Executives are scheduled to present at …
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has expanded its Moments of Clarity program, adding six new personal stories that illuminate the lived experiences of people managing chronic immune-mediated skin conditions, …
Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions Read More WILMINGTON, DE — Incyte will present an expansive slate of research at the 2025 American Society of Hematology (ASH) Annual Meeting, highlighting new data across its myeloproliferative neoplasm (MPN), graft-versus-host …
Incyte Prepares to Showcase Pipeline Momentum With New mutCALR Data at ASH 2025 Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced a series of strategic updates aimed at sharpening its development priorities and extending its financial runway. The biotechnology company has executed …
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has entered into an exclusive option agreement with Incyte Corporation (Nasdaq: INCY) for its mutant-selective JAK2V617F JH2 inhibitor program, a next-generation therapy …
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy Read More